Asia faces a $700 billion threat from antimicrobial resistance by 2050, surpassing cancer as top killer.

A new report by the Centre for Impact Investing and Practices and the World Economic Forum highlights the growing threat of antimicrobial resistance (AMR) in Asia, which could cost up to $700 billion by 2050 and surpass cancer as the leading cause of death. The report recommends cross-sector investment in improving knowledge, strengthening health systems, enhancing surveillance, and researching new antimicrobials. It emphasizes a unified approach to combat AMR and prevent economic and health crises.